TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06770764: Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors

Sponsor: Trutino Biosciences Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 50 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT06770764 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06770764 Rescue Dossier →